| Overexpression of MYB drives proliferation of CYLD‐defective cylindroma cells N Rajan, MK Andersson, N Sinclair, A Fehr, K Hodgson, CJ Lord, ... The Journal of pathology 239 (2), 197-205, 2016 | 45 | 2016 |
| Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth E Scott, K Hodgson, B Calle, H Turner, K Cheung, A Bermudez, ... Oncogene 42 (12), 926-937, 2023 | 37 | 2023 |
| Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome HR Davies, K Hodgson, E Schwalbe, J Coxhead, N Sinclair, X Zou, ... Nature Communications 10 (1), 4717, 2019 | 32 | 2019 |
| ST6GAL1‐mediated aberrant sialylation promotes prostate cancer progression E Scott, E Archer Goode, R Garnham, K Hodgson, M Orozco‐Moreno, ... The Journal of Pathology 261 (1), 71-84, 2023 | 24 | 2023 |
| Understanding inherited cylindromas: clinical implications of gene discovery A Dubois, K Hodgson, N Rajan Dermatologic clinics 35 (1), 61-71, 2017 | 24 | 2017 |
| Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors with pegcantratinib: the TRAC randomized clinical trial M Danilenko, E Stamp, DD Stocken, A Husain, M Zangarini, A Cranston, ... JAMA dermatology 154 (8), 913-921, 2018 | 18 | 2018 |
| Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone K Hodgson, M Orozco-Moreno, EA Goode, M Fisher, R Garnham, ... EBioMedicine 104, 2024 | 11 | 2024 |
| Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors M Orozco-Moreno, EA Visser, K Hodgson, AL Hipgrave Ederveen, ... Glycobiology 33 (12), 1155-1171, 2023 | 11 | 2023 |
| ST3 beta-galactoside alpha-2, 3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer R Garnham, D Geh, R Nelson, E Ramon-Gil, L Wilson, EN Schmidt, ... Communications Biology 7 (1), 276, 2024 | 9 | 2024 |
| The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer K Hodgson, M Orozco-Moreno, E Scott, R Garnham, K Livermore, ... Scientific reports 13 (1), 17031, 2023 | 6 | 2023 |
| Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells EA Goode, M Orozco-Moreno, K Hodgson, A Nabilah, M Murali, Z Peng, ... Cancers 16 (17), 2953, 2024 | 1 | 2024 |
| Epigenetic dysregulation underpins tumorigenesis in a cutaneous tumor syndrome HR Davies, K Hodgson, E Schwalbe, J Coxhead, N Sinclair, X Zou, ... bioRxiv, 687459, 2019 | 1 | 2019 |
| Diverse assays from a single skin punch biopsy to assess topical drug intervention M Danilenko, K Hodgson, R Stones, A Husain, M Zangarini, G Veal, ... British Journal of Dermatology 180 (4), 937-938, 2019 | 1 | 2019 |
| Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha. K Hodgson, J Inns, G Reynolds, E Stephenson, A Paul, N Sinclair, ... bioRxiv, 2025.01. 31.635629, 2025 | | 2025 |
| Using glycan targeting drugs to block prostate cancer bone metastasis K Hodgson, EA Goode, K Bastian, M Fisher, R Garnham, ... GLYCOBIOLOGY 33 (11), 1043-1043, 2023 | | 2023 |
| ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer R Garnham, D Geh, R Nelson, E Ramon-Gill, L Wilson, EN Schmidt, ... bioRxiv, 2023.04. 03.535346, 2023 | | 2023 |
| Mutated epigenetic modifiers in CYLD cutaneous syndrome HR Davies, K Hodgson, E Schwalbe, J Coxhead, N Sinclair, X Zou, ... EUROPEAN JOURNAL OF HUMAN GENETICS 27, 1164-1164, 2019 | | 2019 |
| 277 DNMT3A is an epigenetic negative regulator of Wnt/ß-catenin pathway signalling in CYLD cutaneous syndrome K Hodgson, H Davies, E Schwalbe, J Coxhead, N Sinclair, X Zou, ... Journal of Investigative Dermatology 139 (9), S262, 2019 | | 2019 |
| Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib M Danilenko, E Stamp, DD Stocken, A Husain, M Zangarini, A Cranston, ... JAMA Dermatology, 2018 | | 2018 |
